Neuromodulation for intractable OAB

Neurourology and Urodynamics

Volumn 30, Issue 5, 2011, Pages 766-770

  Apostolidis, Apostolos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Incontinence; Overactive bladder; Pudendal nerve stimulation; Sacral nerve stimulation; Sacral neuromodulation; Tibial nerve stimulation; Urgency

Indexed keywords

BOTULINUM TOXIN A;

BRAIN CORTEX; COST EFFECTIVENESS ANALYSIS; HUMAN; NERVE STIMULATION; NONHUMAN; OVERACTIVE BLADDER; PATIENT ATTITUDE; PATIENT SAFETY; PATIENT SATISFACTION; PHYSICIAN; PROGNOSIS; PSYCHOSOCIAL CARE; PUDENDAL NERVE STIMULATION; QUALITY OF LIFE; REVIEW; SACRAL NERVE STIMULATION; SPINAL REFLEX; TREATMENT RESPONSE; URINARY URGENCY; URINE INCONTINENCE; URODYNAMICS;

ELECTRIC STIMULATION THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; NEURAL PATHWAYS; PATIENT SELECTION; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 79959825466     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.21123     Document Type: Review

References (50)

1. Chartier-Kastler E. Sacral neuromodulation for treating the symptoms of overactive bladder syndrome and non-obstructive urinary retention: >10 years of clinical experience. BJU Int 2008;101:417-23. (Pubitemid 351160925)
2. Wyndaele JJ, Kovindha A, Madersbacher H, et al. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. Paris: Health Publication Ltd; 2009. p. 793-960.
3. Stöhrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81-8.
4. Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: A systematic review. J Urol 2006;175:835-41. (Pubitemid 43199992)
5. Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev 2009; CD004202.
6. Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 1999;162:352-7. (Pubitemid 29434339)
7. Hassouna MM, Siegel SW, Nyeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: A multicenter study on efficacy and safety. J Urol 2000;163:1849-54. (Pubitemid 30366751)
8. Weil EH, Ruiz-Cerda JL, Eerdmans PH, et al. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: A prospective randomized clinical trial. Eur Urol 2000;37:161-71. (Pubitemid 30103068)
9. van Voskuilen AC, Oerlemans DJ, Weil EH, et al. Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: A retrospective single center study. Eur Urol 2006;49:366-72. (Pubitemid 43197883)
10. Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 2000;56:87-91.
11. Shaker HS, Hassouna M. Sacral nerve root neuromodulation: An effective treatment for refractory urge incontinence. J Urol 1998;159:1516-9. (Pubitemid 29117332)
12. Cappellano F, Bertapelle P, Spinelli M, et al. Quality of life assessment in patients who undergo sacral neuromodulation implantation for urge incontinence: An additional tool for evaluating outcome. J Urol 2001;166:2277-80. (Pubitemid 33065273)
13. Amundsen CL, Webster GD. Sacral neuromodulation in an older, urge-incontinent population. Am J Obstet Gynecol 2002;187:1462-5; discussion 1465.
14. Foster RT, Sr., Anoia EJ, Webster GD, et al. In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction. Neurourol Urodyn 2007;26:213-7.
15. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: Outcomes of a prospective, worldwide clinical study. J Urol 2007;178:2029-34. (Pubitemid 47554439)
16. Bolton JF, Harrison SC. Neuromodulation 10 years on: How widely should we use this technique in bladder dysfunction? Curr Opin Urol 2009;19:375-9.
17. Amundsen CL, Romero AA, Jamison MG, et al. Sacral neuromodulation for intractable urge incontinence: Are there factors associated with cure? Urology 2005;66:746-50.
18. Spinelli M, Weil E, Ostardo E, et al. New tined lead electrode in sacral neuromodulation: Experience from a multicentre European study. World J Urol 2005;23:225-9. (Pubitemid 41136046)
19. Kessler TM, Madersbacher H, Kiss G. Prolonged sacral neuromodulation testing using permanent leads: A more reliable patient selection method? Eur Urol 2005;47:660-5.
20. van Kerrebroeck EV, Scheepens WA, de Bie RA, et al. European experience with bilateral sacral neuromodulation in patients with chronic lower urinary tract dysfunction. Urol Clin North Am 2005;32:51-7. (Pubitemid 40215131)
21. Bosch JL. The bion device: A minimally invasive implantable ministimulator for pudendal nerve neuromodulation in patients with detrusor overactivity incontinence. Urol Clin North Am 2005;32:109-12. (Pubitemid 40215138)
22. Buchs NC, Dembe JC, Robert-Yap J, et al. Optimizing electrode implantation in sacral nerve stimulation - An anatomical cadaver study controlled by a laparoscopic camera. Int J Colorectal Dis 2008;23:85-91. (Pubitemid 350142364)
23. Blok BF, Groen J, Bosch JL, et al. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int 2006;98:1238-43. (Pubitemid 44721234)
24. de Groat WC. Integrative control of the lower urinary tract: Preclinical perspective. Br J Pharmacol 2006;147:S25-40.
25. Griffiths D, Apostolidis A. Neurological control of the bladder in health and disease. In: Fowler CJ, Panicker J, Emmanuel A, editors. Pelvic organ dysfunction in neurological disease: Clinical management and rehabilitation. Cambridge: Cambridge University Press; 2010. p. 1-24.
26. Finazzi-Agro E, Rocchi C, Pachatz C, et al. Percutaneous tibial nerve stimulation produces effects on brain activity: Study on the modifications of the long latency somatosensory evoked potentials. Neurourol Urodyn 2009;28:320-4.
27. van Balken MR, Vergunst H, Bemelmans BL. Prognostic factors for successful percutaneous tibial nerve stimulation. Eur Urol 2006;49:360-5. (Pubitemid 43197882)
28. Hijaz A, Vasavada SP, Daneshgari F, et al. Complications and troubleshooting of two-stage sacral neuromodulation therapy: A single-institution experience. Urology 2006;68:533-7. (Pubitemid 44436482)
29. Aboseif SR, Kim DH, Rieder JM, et al. Sacral neuromodulation: Cost considerations and clinical benefits. Urology 2007;70:1069-73; discussion 1073-4.
30. Siddiqui NY, Amundsen CL, Visco AG, et al. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol 2009;182:2799-804.
31. Munoz-Duyos A, Navarro-Luna A, Brosa M, et al. Clinical and cost effectiveness of sacral nerve stimulation for faecal incontinence. Br J Surg 2008;95:1037-43.
32. Dudding TC, Meng Lee E, Faiz O, et al. Economic evaluation of sacral nerve stimulation for faecal incontinence. Br J Surg 2008;95:1155-63.
33. Leong RK, De Wachter S, van Kerrebroeck P. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: A review. Urol Int 2010;84:245-53.
34. Huang JC, Deletis V, Vodusek DB, et al. Preservation of pudendal afferents in sacral rhizotomies. Neurosurgery 1997;41:411-5. (Pubitemid 27327504)
35. Oliver S, Fowler CJ, Mundy A, et al. Measuring the sensations of urge and bladder filling during cystometry in urge incontinence and the effects of neuromodulation. Neurourol Urodyn 2003;22:7-16.
36. Peters KM, Killinger KA, Boguslawski BM, et al. Chronic pudendal neuromodulation: Expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn 2010;29:1267-71.
37. Groen J, Amiel C, Bosch JL. Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: Results of a pilot study with a novel minimally invasive implantable ministimulator. Neurourol Urodyn 2005;24:226-30. (Pubitemid 40617095)
38. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: Results from the SUmiT trial. J Urol 2010;183:1438-43.
39. Schreiner L, dos Santos TG, Knorst MR, et al. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. Int Urogynecol J Pelvic Floor Dysfunct 2010;21:1065-70.
40. Finazzi-Agro E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: A randomized, double-blind, placebo controlled trial. J Urol 2010;184:2001-6.
41. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: Results from the overactive bladder innovative therapy trial. J Urol 2009;182:1055-61.
42. van der Pal F, van Balken MR, Heesakkers JP, et al. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: Is maintenance treatment necessary? BJU Int 2006;97:547-50.
43. MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol 2010;183:234-40.
44. Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of Botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus panel report. Eur Urol 2009;55:100-20.
45. Anger JT, Weinberg A, Suttorp MJ, et al. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: A systematic review of the literature. J Urol 2010;183:2258-64.
46. Kalsi V, Apostolidis A, Popat R, et al. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006;49:528-35. (Pubitemid 43259564)
47. Khan S, Kessler TM, Apostolidis A, et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. J Urol 2009;181:1773-8.
48. Sahai A, Dowson C, Khan MS, et al. Repeated injections of botulinum toxin- A for idiopathic detrusor overactivity. Urology 2010;75:552-8.
49. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006;49:644-50. (Pubitemid 43374724)
50. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: A double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184:2416-22.